Terapia ibrutynibem dla pacjentów z przewlekłą białaczką limfocytową z aberracjami subklonalnymi TP53

Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the blood and bone marrow. This study focuses on patients with CLL who have specific changes in their genes, known as TP53 mutations. These mutations can affect how the disease progresses. The study aims to understand how these genetic changes evolve over time in patients who are receiving treatment.

The treatment being studied is a medication called ibrutinib. Ibrutinib is taken orally, which means it is swallowed in pill form. It is used as a first-line treatment, meaning it is the initial therapy given to patients who have not received other treatments for their CLL. The study will observe patients at various time points, starting from the beginning of the treatment and continuing at regular intervals, to monitor changes in the genetic makeup of the cancer cells.

The main goal of the study is to track how the size of the TP53 mutated subclone—a small group of cancer cells with these specific mutations—changes over time. This will be measured at different weeks and then yearly until the study ends. By doing this, researchers hope to gain a better understanding of how CLL progresses in patients with these genetic changes and how ibrutinib affects this process.